drugset / Trial / NCT05586100
Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study
Phase 2
Active not recruiting
52 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NaSingle-groupOpen-labelTreatment
Summary
This study is the first clinical study of Neoadjuvant and Adjuvant treatment of head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with PD-1 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a foundation for subsequent studies, with important scientific research significance and clinical value.
Timeline
- Start
- 2022-10-13
- Primary completion
- 2025-04-28
- Completion
- 2026-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |